血清表皮生长因子受体水平在垂体腺瘤增殖诊断中的作用

目的　探讨血清表皮生长因子受体 (EGF R)水平与垂体腺瘤患者瘤前病变和肿瘤增殖的关系。方法　采用酶联免疫分析技术对 137例垂体疾病患者的术前血清EGF R胞外区表达水平进行检测。患者中 5例为垂体Rathke囊肿 ,13例垂体增生 ,119例垂体腺瘤患者 ,其中微腺瘤 17例、大腺瘤 6 4例、巨大腺瘤 38例 ,2 8例正常献血者为对照组。结果　血清EGF R水平在垂体增生患者中为194fmol/L± 38fmol/L ,在垂体微腺瘤、垂体大腺瘤、垂体巨大腺瘤患者中分别为 2 19fmol/L± 37fmol/L、32 2fmol/L± 6 6fmol/L、4 2 8fmol/L± 6 2fmol/L ,均明显高于垂体Rathke囊肿患者 (15 2fmol/L± 17fmol/L ,P <0 0 0 0 1)和对照组 (15 9fmol/L± 4 1fmol/L ,P <0 0 5 )。血清EGF R水平与垂体腺瘤大小呈正相关 (r=0 998) ,并在垂体腺瘤患者各组间存在明显差异 (P <0 0 0 0 1)。结论　检测垂体腺瘤患者术前血清EGF R水平可反映肿瘤的增殖状况 ,可能有助于垂体腺瘤和垂体Rathke囊肿的鉴别诊断。建议血清EGF R可作为反映垂体腺瘤增殖的一种分子参考标志     

外周血可溶性CD44V6测定用于侵袭性垂体腺瘤辅助性诊断

目的探讨测定外周血可溶性细胞粘附分子CD44变异体6sCD44v6)含量对侵袭性和非侵袭性垂体腺瘤诊断的价值。方法酶联免疫吸附法测定68例侵袭性垂体腺瘤和100例非侵袭性垂体腺瘤患者外周血sCD44v6的含量。结果侵袭性垂体微腺瘤、大腺瘤和巨大腺瘤患者血清sCD44v6含量分别为44.63±7.21、(34.53±6.41)和(26.34±4.95)ng/ml,非侵袭性垂体微腺瘤、大腺瘤和巨大腺瘤患者分别为60.78±9.61、(57.78±10.00)和(37.22±5.17)ng/ml,均较对照组(68.73±6.00)ng/ml低(P<0.05)。侵袭性垂体微腺瘤、大腺瘤、巨大腺瘤患者外周血sCD44v6含量均较对应的非侵袭性垂体微腺瘤、大腺瘤、巨大腺瘤患者降低,组间差异具有显著意义(P<0.005)。外周血sCD44v6含量随着肿瘤体积增大而降低(P<0.01),尤以侵袭性垂体腺瘤显著,其诊断侵袭性垂体腺瘤符合率达89.71%。结论外周血sCD44v6含量与垂体腺瘤大小和侵袭性生长行为呈负相关,可能对侵袭性垂体大腺瘤、巨大腺瘤的诊断、治疗决策和判断预后具有一定的参考价值。     

侵袭性垂体腺瘤与Cox-2及VEGF表达的关系

目的研究侵袭性垂体腺瘤侵袭鞍底、海绵窦及鞍上的MRI表现与Cox-2、VEGF表达水平的相关性。方法收集手术及病理证实的60例垂体腺瘤的标本及影像学资料(MRI表现),其中侵袭性垂体腺瘤30例和非侵袭性垂体腺瘤30例,应用免疫检测法测Cox-2及VEGF表达情况,评价Cox-2及VEGF表达水平与肿瘤向海绵窦、鞍上、鞍底侵袭程度的相关性。结果 30例侵袭性垂体腺瘤中,Cox-2呈高表达26例,低表达4例,VEGF呈高表达24例,低表达6例;30例非侵袭性垂体腺瘤中,Cox-2呈高表达14例,低表达的16例,VEGF呈高表达13例,低表达17例;在垂体腺瘤相关MRI侵袭表现中,向海绵窦及鞍底方向生长的不同程度间Cox-2表达差异有统计学意义(P<0.05);向鞍上方向生长不同程度间Cox-2表达差异有统计学意义(P<0.05),VEGF表达差异无统计学意义(P>0.05)。结论 Cox-2、VEGF在垂体腺瘤中表达异常与垂体腺瘤侵袭性有关;垂体腺瘤MRI侵袭特征与Cox-2及VEGF表达有关。     

表皮生长因子受体在垂体腺瘤中的表达和临床意义

目的在垂体腺瘤组织中检测表皮生长因子受体(EGFR)的表达水平并分析其与临床病理类型、肿瘤增殖情况、侵袭性等的关系,为垂体瘤诊断和治疗提供理论依据和临床指导。方法选取65例垂体腺瘤患者术前血清、15例正常志愿者血清,采用酶联免疫分析技术对其EGFR水平进行检测。结果①EGFR水平在侵袭性组为(11.58±0.72)ng/mL、非侵袭性组为(11.44±0.68)ng/mL,与对照组(11.26±0.87)ng/mL相比有明显差异(P<0.05),且侵袭性组明显高于非侵袭性组(P<0.05)。②EGFR水平在垂体微腺瘤组、垂体大腺瘤组、垂体巨大腺瘤组中分别为(11.36±0.17)ng/mL、(11.45±0.69)ng/mL、(11.67±0.62)ng/mL,与对照组(11.26±0.87)ng/mL相比有明显差异(P<0.05);EGFR在垂体腺瘤各组间存在明显差异(P<0.001),且与垂体腺瘤大小呈正相关。③EGFR水平在功能性垂体腺瘤组为(11.52±0.52)ng/mL,与非功能性垂体腺瘤组(11.48±0.71)ng/mL比较无明显差异(P>0.05),且功能性垂体腺瘤各组中无明显差异。结论术前EGFR的检测可以在一定程度上反映垂体腺瘤的增殖情况,术前EGFR的检测有可能成为诊断垂体腺瘤侵袭性和评估预后的良好生物学指标。     

VEGF和MMP-2在垂体腺瘤中的表达及其相互关系的研究

目的:探讨血管内皮生长因子(VEGF)和基质金属蛋白酶-2(MMP-2)在垂体腺瘤中的表达及其与垂体腺瘤侵袭性的相关性.方法用免疫组化SP法和RT-PCR方法对55例垂体腺瘤标本的VEGF及MMP-2表达进行研究,分析其表达与侵袭性垂体腺瘤的关系及两者之间的相关性.结果 VEGF在侵袭性垂体腺瘤中的强阳性及阳性表达率分别为56.3%和100%,明显高于非侵袭性垂体腺瘤中的17.4%和56.5%(P＜0.05),MMP-2在侵袭性垂体腺瘤中的强阳性及阳性表达率分别为65.6%和93.8%,明显高于非侵袭性垂体腺瘤中的13.0%和43.5%(P＜0.01).侵袭性垂体腺瘤组中VEGF mRNA的表达明显高于非侵袭性垂体腺瘤组(0.768±0.050,0.209±0.032,P＜0.01),侵袭性垂体腺瘤组中MMP-2 mRNA的表达明显高于非侵袭性垂体腺瘤组(1.126±0.081,0.425±0.083,P＜0.01).侵袭性腺瘤组中MMP-2与VEGF的表达成正相关(r=0.463,P＜0.01),非侵袭性腺瘤组中MMP-2与VEGF的表达无明显相关性.结论 MMP-2及VEGF的高表达与垂体腺瘤的侵袭性密切相关.MMP-2与VEGF在肿瘤侵袭及新生血管形成过程中存在着内在联系.     

血管内皮生长因子在侵袭性垂体腺瘤中的表达及其临床意义

【目的】探讨血管内皮生长因子(VEGF)在侵袭性垂体腺瘤和非侵袭性垂体腺瘤中的表达及其临床意义。【方法】应用免疫组化法检测26例侵袭垂体腺瘤和20例非侵袭性垂体腺瘤中VEGF的表达,并结合临床资料分析。【结果】VEGF在侵袭性垂体腺瘤的表达明显高于在非侵袭性垂体腺瘤中的表达,VEGF的表达水平与垂体腺瘤的侵袭性呈正相关系。【结论】VEGF垂体腺瘤侵袭性生长及复发相关,是影响预后的重要因素之一,并为临床可靠的标记物。     

垂体腺瘤中激素受体ER、PR和生长因子VEGF、bFGF表达与肿瘤分型、侵袭性关系的研究

目的分析激素受体ER,PR及生长因子VEGF,bFGF在垂体腺瘤中的表达,探讨ER,PR,VEGF,bFGF与垂体腺瘤分型及侵袭性之间的关系。方法取经手术切除且病理诊断为垂体腺瘤、具有完整内分泌资料的患者80例,根据Hardy-Wilson及Knosp分级、分期标准,结合病理活检判断其肿瘤侵袭性,将肿瘤的侵袭程度分为0、1、2、3级,分别为10例、11例、30例和29例。用免疫组化方法分别检测每例肿瘤ER,PR,VEGF和bFGF的表达水平,用RT-PCR检测VEGF和bFGF mRNA的表达。结果 80例患者中ER,PR表达的阳性率分别为62.5%(50/80)和60%(48/80);PRL腺瘤与无功能腺瘤之间ER蛋白表达阳性率的呈显著性差异(P<0.05),PR表达水平与垂体腺瘤分型相关性不显著(P>0.05)。随肿瘤侵袭性程度的增加,VEGF和bFGFmR NA的表达和免疫组化阳性率及分级相应增加。结论 ER的表达水平与PR L型垂体腺瘤有关,其表达水平有可能作为判断PR L型垂体腺瘤发生和预后的指标。生长因子VEGF和bFGF mR NA、蛋白的表达也与垂体腺瘤侵袭性密切相关,有可能作为抑制垂体腺瘤侵袭性的治疗靶标。     

血清中VEGF与AFP联合检测在原发性肝癌辅助诊断中的研究

目的 探讨血清中VEGF和AFP联合检测在原发性肝癌辅助诊断中的应用.方法 应用双抗体夹心ELISA法对38例原发性肝癌患者进行血清VEGF水平测定,并以24例肝硬化患者和25名正常人做比较.结果 正常人血清VEGF水平为(78.9±24.2)pg/ml;肝硬化患者血清VEGF水平为(102.6±47.6)pg/ml;38例肝癌患者血清VEGF为(444.8±220.9)pg/ml.肝癌患者的外周血VEGF水平显著高于正常人和肝硬化患者(P＜0.01);肝硬化与正常人无显著差别(P＞0.05).血清VEGF的水平与AFP无相关性;AFP联合VEGF检测时阳性率由单项的76.3%提高到84.9%.结论 VEGF是相对独立的指标,与AFP联合检测可以提高原发性肝癌的检出率.     

卵巢上皮性肿瘤患者血清血管内皮生长因子的诊断及预后意义

目的探讨术前血清血管内皮生长因子(VEGF)检测在卵巢上皮性肿瘤诊断及预后判断方面的价值.方法利用酶联免疫吸附分析(ELISA)检测卵巢上皮性肿瘤患者(恶性47例,良性14例)术前血清VEGF浓度,11例正常妇女的血清作为对照.分析检测结果与临床资料的关系.结果血清VEGF检测结果,恶性组血清VEGF均值221.81 pg/ml(95%置信区间(CI)180.35～262.87 pg/ml),良性组均值158.21 pg/ml(95%CI 27.32～279.10 pg/ml),正常对照组均值121.48 pg/ml(95%CI 34.13～228.32 pg/ml).三组血清VEGF均数差异无显著性(P＞0.05).47例恶性上皮性卵巢肿瘤中,晚期患者(38例)的术前血清VEGF浓度比早期患者(9例)的高,差异有显著性(P＜0.05).肿瘤分化程度差(G3)的患者术前血清VEGF浓度高于肿瘤分化程度高(G1-2)的(P＜0.05).不同病理类型的患者术前血清VEGF水平无统计学差异(P＞0.05).对29例已经进行彻底的肿瘤细胞减灭术的患者随访,术前血清VEGF水平高的患者2年内肿瘤复发或远处转移的可能较大(P＜0.05).结论术前血清VEGF可能对反映患者的预后有一定价值.     

垂体腺瘤中CXCR4、VEGF的表达及其与侵袭性之间的关系

目的观察基质细胞衍生趋化因子-1（SDF-1）受体CXCR4及血管内皮生长因子（VEGF）在垂体腺瘤中表达水平,为侵袭性垂体腺瘤的治疗提供理论和实验依据。方法采用免疫组化SABC方法检测9例非侵袭垂体腺瘤及39例侵袭性垂体腺瘤（Ⅰ级15例,Ⅱ级14例,Ⅲ级10例）瘤组织中CXCR4及VEGF水平。采用多功能真彩色病理分析系统进行免疫组化分析。结果 39例侵袭性垂体腺瘤和9例非侵袭性垂体腺瘤均可见CXCR4和VEGF的表达。非侵袭性垂体腺瘤患者与侵袭性垂体腺瘤患者比较,CXCR4和VEGF的表达差异均有统计学意义（P〈0.05）,Ⅲ级侵袭腺瘤的CXCR4及VEGF表达均高于Ⅰ级与Ⅱ级侵袭性垂休腺瘤及非侵袭性垂体腺瘤,差异有统计学意义（P〈0.05）,Ⅱ级侵袭性垂体腺瘤表达高于非侵袭垂体腺瘤,差异有统计学意义（P〈0.05）。CXCR4的表达与VEGF的表达之间存在明显相关（r=0.653,P〈0.01）。结论 CXCR4及VEGF在侵袭性垂体腺瘤的表达明显高于非侵袭性垂体腺瘤,且随着侵袭程度的加剧而增高,与垂体腺瘤的侵袭性相关;CXCR4与VEGF呈正的直线相关关系,对垂体腺瘤的侵袭性生物学行为的评估有重要意义,并为临床制定合理的治疗方案、预后判断及疗效评定提供客观参考依据。     

ELEVATED SOLUBLE EPIDERMAL GROWTH FACTOR RECEPTOR LEVEL IN PITUITARY ADENOMA AND CARCINOMA

Objective To investigate effect of the soluble epidermal growth factor receptor (sEGFR/sErbB1) level in the peripheral blood in development, invasiveness, apoplexy of each type of pituitary tumor.Methods The sEGFR level was determined in peripheral serum from 190 patients with pituitary diseases by enzyme linked immunosobent assay. The sEGFR levels were measured in 10 pituitary Rathke's pouch, 18 pituitary hyperplasia, 161pituitary adenomas including 30 microadenomas, 83 large adenomas, 48 giant adenomas, 1 pituitary carcinoma, and 28 healthy controls.Results In the patients with pituitary hyperplasia, microadenoma, large adenoma, giant adenoma, and pituitary carcinoma, the sEGFR level was 188.92 32.62, 209.83 19.01,333.20 69.33, 405.85 37.38, and 617.45 fmol/mL independently. They were all significantly higher than patients with pituitary Rathke's pouch (156.78 18.24 fmol/mL, P ＜ 0.001)and healthy control group (159.11 40.50 fmol/mL, P ＜ 0.05). The sEGFR level in pituitary carcinoma was higher than pituitary adenoma. In patients with pituitary adenoma, the sEGFR level was positive correlated to the size of pituitary adenomas (r = 0.998), the significant difference was observed for the sEGFR level in each group of the patients with pituitary adenomas (P ＜ 0.001). Furthermore, in patients with pituitary ACTH-secrefing microadenomas, the serum sEGFR levels in invasiveness (295.00 77.80 fmol/mL) was higher than that in non-invasiveness (210.60 16.4 fmol/mL, P ＜ 0.05). In patients with pituitary ACTH-secreting, PRL-secreting, GH-secreting, and non-functioning large adenomas, the serum sEGFR levels in invasiveness (407.86 28.50, 399.25 30.10, 386.00 13.08, and 369.25 36.70 fmol/mL) was higher than that in non-invasiveness (335.25 63.49, 300.64 47.57, 297.00 61.93, and 269.30 25.68 fmol/mL) respectively (P ＜ 0.05). In patients with invasive pituitary PRL-secreting, GH-secreting, and non-functioning giant adenomas, the serum sEGFR levels not significantly different in between invasiveness (417.50 35.94, 409.50 69.14, and 417.50 44.13 fmol/mL) and noninvasiveness (386.00 49.64, 417.50 44.03, and 409.51 35.17 fmol/mL) (P ＞ 0.05). In patients with pituitary large adenomas, the sEGFR levels in pituitary apoplexy (377.48 39.18 fmol/mL) was higher than that in non-pituitary apoplexy(343.18 68.17 fmol/mL, P ＞ 0.05).Conclusions The increased level of peripheral serum sEGFR is concomitant with development, proliferous size of the adenomas in patients with pituitary adenomas. In addition, the elevated levels of serum sEGFR occur in pituitary apoplexy as clinical active tumors, and the non-invasive ACTH secreting adenomas. The sEGFR levels could be differentiated helpfully between pituitary adenomas and non-pituitary adenomas. These data suggest that serum sEGFR could be as a referable marker of the size and activation of proliferation in pituitary adenoma.     

血管内皮生长因子及其受体表达水平下调增加垂体腺瘤卒中风险

目的 探讨血管内皮生长因子(vascular endothelial growth factor,VEGF)及其受体在垂体腺瘤中的表达与垂体腺瘤卒中之间的关系。方法 本实验运用实时定量核酸扩增检测系统(real-time quantitative PCR,QPCR)检测了166例垂体腺瘤标本中VEGF及其受体mRNA的表达,结合病理结果,免疫组织化学和临床资料特点分组进行统计学分析。结果 出现肿瘤卒中的无功能腺瘤中VEGF和VEGF-3的表达水平降低与肿瘤卒中有关(P<0.05);VEGF-1和VEGFR-2表达水平与肿瘤卒中无明显相关(P>0.05)。结论 无功能垂体腺瘤的VEGF和VEGFR-3的表达下降与垂体腺瘤卒中有关。     

Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma

Objectives To determine the pre-therapeutic serum level of vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma (HCC) and to elucidate the relation between the serum level and clinical characteristics and metastasis of HCC. Methods One-hundred and fifteen HCC patients, 40 patients with benign liver lesions, and 30 healthy control subjects were included in this study. The serum VEGF level was measured with the quantitative sandwich enzyme linked immunosorbent assay (ELISA, R&amp;D systems). Results The serum VEGF levels in the HCC group (465.62±336.24 pg/ml) was significantly elevated as compared with those in patients with benign liver lesions (159.54±120.58 pg/ml) and those in normal controls (123.53±51.84 pg/ml). The VEGF levels were not significantly different between the patients with benign liver lesions and the normal controls. The serum VEGF concentration showed a positive rate of 77.4%, 25%, and 3.3% in the HCC patients, benign liver lesion patients and normal controls, respectively. In the 115 HCC patients, the serum VEGF levels in patients with portal vein (PV) emboli (n=26, 582.76±441.89 pg/ml), with metastasis (n=43, 548.29±438.57 pg/ml) or with large HCC lesions (≥5 cm in diameter) (n=69, 554.43±369.99 pg/ml) were significantly higher than those without PV-emboli (n=89, 431.39±292.84 pg/ml), without metastasis (n=72, 416.24±247.27 pg/ml) or with small HCC lesions (n=42, 328.67±227.47 pg/ml). The serum VEGF levels in stage Ⅰ, Ⅱ, Ⅲ, Ⅳa and Ⅳb HCC patients were 340.6 pg/ml, 451.55±307.84 pg/ml, 397.44±257.18 pg/ml, 486.10±397.73 pg/ml and 647.93±344.56 pg/ml, respectively. Conclusion The pre-therapeutic serum VEGF levels in HCC patients appear to reflect the disease’s potential activity of vascular invasion and metastasis.     

The role of serum leptin and tumor necrosis factor-α in malnutrition of male chronic obstructive pulmonary disease patients

Background Leptin is a protein mainly secreted by adipocytes, and the major function of leptin was its role in body weight regulation. It is suggested that increased levels of circulating leptin may contribute to anorexia in pathologic conditions including chronic obstructive pulmonary disease (COPD). Recent studies have provided evidence for a link between leptin and proinflammatory cytokines such as tumor necrosis factor-α (TNF-α). This study aimed to explore the role of serum leptin in the malnutrition of COPD patients, and to observe the changes of serum leptin levels during acute exacerbation, also to investigate relationship between leptin and TNF-α. Methods Seventy-two COPD patients and 34 control subjects participated in this study. Seventy-two COPD patients were divided into 3 groups: group COPD IA (patients without malnutrition during acute exacerbation, n=25), group COPD IB (patients without malnutrition during stable disease, n=29), group COPD II (patients with malnutrition during stable disease, n=18). To eliminate the effect of sex differences, all patients and controls were male. Body mass index (BMI), percent ideal body weight (IBW％), triceps skin-fold thickness (TSF), mid-upper arm circumference (MAC), mid-upper arm muscle circumference (MAMC), serum leptin and TNF-α levels, serum prealbumin (PA), serum transferrin (TF), serum albumin (Alb), total lymphocytes count (TLC), forced expiratory volume in one second (FEV(1)), maximal inspiration pressure (MIP) and maximal expiration pressure (MEP) were measured in all participants. Leptin levels were measured by radioimmunoassay. TNF-α levels were measured by ELISA. The between group difference and correlation of these parameters were analyzed. Results Serum leptin levels were significantly lower in group COPD II [(4.07±3.42) ng/ml] than in group COPD IB [(9.72±6.67) ng/ml] and controls [(8.21±5.41) ng/ml] (P&lt;0.05). There was no statistically significant difference in serum leptin levels between group COPD IA [(10.82±6.40) ng/ml], group COPD IB [(9.72±6.67) ng/ml] and controls [(8.21±5.41) ng/ml]. There was no statistically significant difference in serum TNF-α levels between group COPD II [(8.03±3.37) pg/ml], group COPD IA [(8.90±1.60) pg/ml], and group COPD IB [(7.25±2.08) pg/ml]. There was no significant correlation between leptin and TNF-α in any group. Conclusions Leptin was not involved in anorexia and weight loss of COPD patients. There was no statistically significant difference in serum leptin levels between COPD patients during stable stage and acute exacerbation, and there was no significant correlation between TNF-α and leptin during the regulation of the energy balance in COPD patients.     

PAPP-A及VEGF在子痫前期患者血清中的表达及其相关性研究

目的 观察子痫前期患者血清中妊娠相关血浆蛋白A (PAPP-A)及血清血管内皮生长因子(VEGF)表达情况,探讨其与子痫前期病情严重程度的关系.方法 选择2013年1月至2014年12月在上海市浦东医院门诊行常规产前检查并分娩的子痫前期孕妇60例为子痫前期组,根据病情严重程度将其分为轻度子痫前期组30例,重度子痫前期组30例.选取同期行本院门诊产前检查并住院分娩的正常孕妇30例为对照组.分别采用酶联免疫吸附试验测定三组孕妇血清中的PAPP-A水平和VEGF的水平,分析其与子痫前期患者病情严重程度的关系.结果 重度子痫前期组新生儿出生体重[(3.4±0.5) kg]低于轻度子痫前期组[(3.6±1.4) kg]和对照组[(3.7±0.5) kg],差异均具有统计学意义(P<0.05);重度子痫前期组患者血清PAPP-A值、VEGF值和24 h尿蛋白值分别为(900.6 ± 379.0) μg/ml、(7.2±4.2) pg/ml、(2.5±1.2) g/24 h,轻度子痫前期组分别为(783.8±204.7) μg/ml、(5.3±1.4) pg/ml、(1.4±0.3) g/24 h,均分别高于对照组的(592.9±222.9) μg/ml、(4.8±2.8) pg/ml、(0.2±0.1) g/24 h,差异均具有统计学意义(P<0.05);重度子痫前期组的血清PAPP-A值和24 h尿蛋白值均高于轻度子痫组,差异具有统计学意义(P<0.05);Speraman相关分析显示,血清PAPP-A值和血清VEGF值呈明显的正相关(r=0.574,P<0.05).结论 PAPPA及VEGF均参与了子痫前期的发生及发展.     

系统性红斑狼疮患者血清IL-18、sVCAM-1和VEGF水平及其意义

目的探讨白细胞介素18(IL-18)、可溶性血管黏附分子-1(sVCAM-1)和血管内皮生长因子(VEGF)水平变化与系统性红斑狼疮(SLE)发病机制的关系。方法采用酶联免疫ELISA法检测SLE患者35例,正常对照组25例血清IL-18、sVCAM-1和VEGF的水平。结果SLE组IL-18(521.23±134.29)pg/mL、sVCAM-1(1179.25±225.57)ng/mL、VEGF(198.85±41.96)pg/mL,较正常对照组IL-18(256.39±59.52)pg/mL、sVCAM-1(538.16±91.21)ng/mL、VEGF(125.62±32.15)pg/mL明显升高,差异有统计学意义(P均<0.01)。活动期SLE患者IL-18(687.44±158.60)pg/mL、sVCAM-1(1478.14±322.72)ng/mL、VEGF(236.25±48.62)pg/mL与非活动期组SLEIL-18(355.02±109.98)pg/mL、sVCAM-1(881.37±128.30)ng/mL、VEGF(160.47±35.79)pg/ml之间比较,差异有统计学意义(P...     

SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN PATIENTS WITH ANGINA PECTORIS AND ACUTE MYOCARDIAL INFARCTION

ＩＮＴＲＯＤＵＣＴＩＯＮ　　Ｖａｓｃｕｌａｒｅｎｄｏｔｈｅｌｉａｌｇｒｏｗｔｈｆａｃｔｏｒ (ＶＥＧＦ)ｏｒｖａｓｃｕｌａｒｐｅｒｍｅａｂｉｌｉｔｙｆａｃｔｏｒ (ＶＰＦ)ｃｏｎｓｉｓｔｓｏｆａｆａｍｉｌｙｏｆｐｏｌｙｐｅｐｔｉｄｅｉｓｏｆｏｒｍｓｔｈａｔｓｐｅｃｉｆｉｃａｌｌｙｒｅｇｕｌａｔｅｅｎｄｏｔｈｅｌｉａｌｃｅｌｌｆｕｎｃｔｉｏｎ ,ｉｎｃｌｕｄｉｎｇｅｎｈａｎｃｅｍｅｎｔｏｆａｎｇｉｏｇｅｎｅｓｉｓ( 1) ,ｅｎｈａｎｃｅｍｅｎｔｏｆｍｉｃｒｏｖａｓｃｕｌａｒｐｅｒｍｅａｂｉｌｉｔｙ ( 2 ) ,ａｎ…     

Association of IL-7 with disease progression in Chinese HIV-1 seropositive individuals

Background Elevated levels of interleukin-7 (IL-7) have been correlated with CD4(+) T cell depletion and the emergence of syncytium-inducing (SI) variants in human immunodeficiency virus type-1 (HIV-1) infection, and suggested as an indicator of acquired immunodeficiency syndrome (AIDS) disease progression. Therefore, we investigated the effects of IL-7 on disease progression and virus phenotype in Chinese HIV/AIDS patients. Methods In a cross-sectional study of 71 untreated HIV-1 seropositive individuals and 12 healthy donors, plasma IL-7 levels were determined by an ultra sensitive enzyme-linked immunosorbent assay (ELISA), and its relations to CD4(+) T cells, CD8(+) T cells, plasma viral loads and HIV phenotypes were analyzed. Results Significant higher IL-7 levels were found in Chinese HIV/AIDS patients [(3.33 ± 3.60) pg/ml] than those of health controls [(1.2 ± 0.81) pg/ml] ( P &lt;0.05), and IL-7 levels were inversely associated with CD4(+) T cell counts ( r = － 0.497, P &lt;0.01). Furthermore, IL-7 levels were significant higher in patients with SI variants [(9.12 ± 4.55) pg/ml] than those with non-syncytium-inducing variants [(1.50 ± 2.69) pg/ml] ( P &lt;0.01). Conclusions Increased IL-7 levels were found in Chinese HIV/AIDS patients and significantly associated with disease progression, thus increased IL-7 plasma levels may indicate disease progression.